Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01030861
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:37.805293+00:00
Published At
2020-08-05T00:00:00+00:00
Record Updated At
2020-08-05
Results Posted At
2020-08-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Autoantibody Positive", "Non-diabetic Relatives at Risk for Type 1 Diabetes", "High Risk", "Impaired Glucose Tolerance"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-08-05"
protocolSection.identificationModule.nctId
"NCT01030861"
protocolSection.identificationModule.officialTitle
"AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-08-05"

Study condition terms

  • Autoantibody Positive (protocolSection.conditionsModule.conditions)
  • Non-diabetic Relatives at Risk for Type 1 Diabetes (protocolSection.conditionsModule.conditions)
  • High Risk (protocolSection.conditionsModule.conditions)
  • Impaired Glucose Tolerance (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.